Residual Viremia in Treated HIV+Individuals

PLoS Computational Biology

Volumn 12, Issue 1, 2016, Pages

  Conway, Jessica M ^a   Perelson, Alan S ^b  

^a PENNSYLVANIA STATE UNIVERSITY   (United States)

^b LOS ALAMOS NATIONAL LABORATORY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CHEMICAL ACTIVATION; DISEASES; DYNAMICS; LONG TERM EVOLUTION (LTE); STOCHASTIC MODELS; STOCHASTIC SYSTEMS;

ANTIRETROVIRALS; DRUG-RESISTANCE; HIV INFECTION; HIV VIRAL LOADS; INFECTED CELLS; INFECTED PATIENTS; LEVELS OF DETECTIONS; PHYLOGENETIC ANALYSIS; SHORT TERM; VIRAL REPLICATION;

VIRUSES;

EMTRICITABINE; RALTEGRAVIR; TENOFOVIR DISOPROXIL; ANTIRETROVIRUS AGENT; VIRUS RNA;

ANTIVIRAL RESISTANCE; ARTICLE; CONTROLLED STUDY; DRUG EFFICACY; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IN VIVO STUDY; MOLECULAR DYNAMICS; NONHUMAN; PHYLOGENY; STOCHASTIC MODEL; VIRUS LOAD; VIRUS REPLICATION; VIRUS STRAIN; BIOLOGICAL MODEL; BIOLOGY; DRUG EFFECTS; GENETICS; HIV INFECTIONS; HUMAN IMMUNODEFICIENCY VIRUS 1; PHYSIOLOGY; VIREMIA; VIROLOGY;

ANTI-RETROVIRAL AGENTS; COMPUTATIONAL BIOLOGY; HIV INFECTIONS; HIV-1; HUMANS; MODELS, BIOLOGICAL; RNA, VIRAL; VIRAL LOAD; VIREMIA; VIRUS REPLICATION;

EID: 84956780091     PISSN: 1553734X     EISSN: 15537358     Source Type: Journal    
DOI: 10.1371/journal.pcbi.1004677     Document Type: Article

References (61)

1. Chun TW, Davey RT, Engel D, Lane HC, Fauci AS, Re-emergence of HIV after stopping therapy. Nature. 1999;401:874–875. doi: 10.1038/44755 10553903
2. Maldarelli F, Palmer S, King MS, Wiegand A, Polis MA, Mican J, et al. ART suppresses plasma HIV-1 RNA to a stable set point predicted by pretherapy viremia. PLoS Pathog. 2007;3(4):e46. doi: 10.1371/journal.ppat.0030046 17411338
3. Luo R, Cardozo EF, Piovoso MJ, Wu H, Buzón MJ, Martinez-Picado J, et al. Modeling HIV-1 2-LTR dynamics following raltegravir intensification. J Roy Soc Interface. 2013;10:20130186. doi: 10.1098/rsif.2013.0186
4. Chun TW, Carruth L, Finzi D, Shen X, DiGiuseppe JA, Taylor HY, et al. Quantification of latent tissue reservoirs and total body viral load in HIV-1 infection. Nature. 1997;387:183–188. doi: 10.1038/387183a0 9144289
5. Finzi D, Blankson J, Siliciano JD, Margolick JB, Chadwick K, Pierson T, et al. Latent infection of CD4+ T cells provides a mechanism for lifelong persistence of HIV-1, even in patients on effective combination therapy. Nat Med. 1999;5(5):512–517. doi: 10.1038/8394 10229227
6. Ananworanich J, Dubé K, Chomont N, How does the timing of antiretroviral therapy initiation in acute infection affect HIV reservoirs? Curr Opin HIV AIDS. 2015;10:18–28.
7. Chun TW, Engel D, Berrey MM, Shea T, Corey L, Fauci AS, Early establishment of a pool of latently infected, resting CD4+ T cells during primary HIV-1 infection. Proc Natl Acad Sci USA. 1998;95(15):8869–8873. doi: 10.1073/pnas.95.15.8869 9671771
8. Whitney JB, Hill AL, Sanisetty S, Penaloza-MacMaster P, Liu J, Shetty M, et al. Rapid seeding of the viral reservoir prior to SIV viraemia in rhesus monkeys. Nature. 2014;512:74–77. doi: 10.1038/nature13594 25042999
9. Chomont N, El-Far M, Ancuta P, Trautmann L, Procopio FA, Yassine-Diab B, et al. HIV reservoir size and persistence are driven by T cell survival and homeostatic proliferation. Nat Med. 2009;15(8):893–901. doi: 10.1038/nm.1972 19543283
10. Siliciano JD, Kajdas J, Finzi D, Quinn TC, Chadwick K, Margolick JB, et al. Long-term follow-up studies confirm the stability of the latent reservoir for HIV-1 in resting CD4+ T cells. Nat Med. 2003;9(6):727–728. doi: 10.1038/nm880 12754504
11. Richman DD, Margolis DM, Delaney M, Greene WC, Hazuda D, Pomerantz RJ, The Challenge of Finding a Cure for HIV Infection. Science. 2009;323:1304–1307. doi: 10.1126/science.1165706 19265012
12. Chun TW, Engel D, Mizell SB, Ehler LA, Fauci AS, Induction of HIV-1 replication in latently infected CD4+ T cells using a combination of cytokines. J Exp Med. 1998;188(1):83–91. doi: 10.1084/jem.188.1.83 9653086
13. Coiras M, López-Huertas MR, Pérez-Olmeda M, Alcamí J, Understanding HIV-1 latency provides clues for the eradication of long-term reservoirs. Nat Rev Microbiol. 2009;7:798–812. doi: 10.1038/nrmicro2223 19834480
14. Pierson T, McArthur J, Siliciano RF, Reservoirs for HIV-1: Mechanisms for viral persistence in the presence of antiviral immune responses and antiretroviral therapy. Annu Rev Immunol. 2000;18:665–708. doi: 10.1146/annurev.immunol.18.1.665 10837072
15. Hatano H, L HT, Dahl V, Sinclair E, Lee TH, Hoh R, et al. A randomized, controlled trial of raltegravir intensification in antiretroviral-treated, HIV-infected patients with a suboptimal CD4+ T cell response. J Infect Dis. 2011;203:960–968. doi: 10.1093/infdis/jiq138 21402547
16. Dinoso JB, Kim SY, Wiegand AM, Palmer SE, Gange SJ, Cranmer L, et al. Treatment intensification does not reduce residual HIV-1 viremia in patients on highly active antiretroviral therapy. Proc Natl Acad Sci USA. 2009;106:9403–9408. doi: 10.1073/pnas.0903107106 19470482
17. Kieffer TL, Finucane MM, Nettles RE, Quinn TC, Broman KW, Ray SC, et al. Genotypic analysis of HIV-1 drug resistance at the limit of detection: virus production without evolution in treated adults with undetectable HIV loads. J Infect Dis. 2004;189:1452–1465. doi: 10.1086/382488 15073683
18. Hermankova M, Ray SC, Ruff C, Powell-Davis M, Ingersoll R, D’Aquila RT, et al. HIV-1 drug resistance profiles in children and adults with viral load of <50 copies/mL receiving combination therapy. J Amer Med Assoc. 2001;286:196–207. doi: 10.1001/jama.286.2.196
19. Anderson JA, Archin NM, Ince W, Parker D, Wiegand A, Coffin JM, et al. Clonal sequences recovered from plasma from patients with residual HIV-1 viremia and on intensified antiretroviral therapy are identical to replicating viral RNAs recovered from circulating resting CD4+ T cells. J Virol. 2011;85:5220–5223. doi: 10.1128/JVI.00284-11 21367910
20. Bailey JR, Sedaghat AR, Kieffer T, Brennan T, Lee PK, Wind-Rotolo M, et al. Residual human immunodeficiency virus type 1 viremia in some patients on antiretroviral therapy Is dominated by a small number of invariant clones rarely found in circulating CD4+ T cells. J Virol. 2006;80:6441–6457. doi: 10.1128/JVI.00591-06 16775332
21. Evering TH, Mehandru S, Racz P, Tenner-Racz K, Poles MA, Figueroa A, et al. Absence of HIV-1 evolution in the gut-associated lymphoid tissue from patients on combination antiviral therapy initiated during primary infection. PLoS Pathog. 2012;8:e1002506. doi: 10.1371/journal.ppat.1002506 22319447
22. Joos B, Fischer M, Kuster H, Pillai SK, Wong JK, Boeni J, et al. HIV rebounds from latently infected cells, rather than from continuing low-level replication. Proc Natl Acad Sci USA. 2008;105(43):16725–16730. doi: 10.1073/pnas.0804192105 18936487
23. Llibre JM, Buzón MJ, Massanella M, Esteve A, Dahl V, Puertas MC, et al. Treatment intensification with raltegravir in subjects with sustained HIV-1 viraemia suppression: a randomized 48-week study. Antivir Ther. 2012;17:355–364. 22290239
24. Chun TW, Murray D, Justement JS, Hallahan CW, Moir S, Kovacs C, et al. Relationship between residual plasma viremia and the size of HIV proviral DNA reservoirs in infected individuals receiving effective antiretroviral therapy. J Infect Dis. 2011;204:135–138. doi: 10.1093/infdis/jir208 21628667
25. Fletcher CV, Staskus K, Wietgrefe SW, Rothenberger M, Reilly C, Chipman JG, et al. Persistent HIV-1 replication is associated with lower antiretroviral drug concentrations in lymphatic tissues. Proc Natl Acad Sci USA. 2014;111:2307–2312. doi: 10.1073/pnas.1318249111 24469825
26. Rong L, Perelson AS, Asymmetric division of activated latently infected cells may explain the decay kinetics of the HIV-1 latent reservoir and intermittent viral blips. Math Biosci. 2009;217:77–87. doi: 10.1016/j.mbs.2008.10.006 18977369
27. NIH. AIDSinfo: Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents; 2015.
28. Perelson AS, Kirschner DE, De Boer RJ, Dynamics of HIV-infection of CD4+ T-cells. Math Biosci. 1993;114(1):81–125. doi: 10.1016/0025-5564(93)90043-A 8096155
29. Perelson AS, Neumann AU, Markowitz M, Leonard JM, Ho DD, HIV-1 dynamics in vivo: Virion clearance rate, infected cell life-span, and viral generation time. Science. 1996;271(5255):1582–1586. doi: 10.1126/science.271.5255.1582 8599114
30. Stafford MA, Corey L, Cao Y, Daar ES, Ho DD, Perelson AS, Modeling plasma virus concentration during primary HIV infection. J Theor Biol. 2000;203:285–301. doi: 10.1006/jtbi.2000.1076 10716909
31. Vaidya NK, Ribeiro RM, Miller CJ, Perelson AS, Primary SIV infection: effect of time-dependent virus infectiousness. J Virol. 2010;84:4302–4310. doi: 10.1128/JVI.02284-09 20147390
32. Vaidya NK, Rong L, Marconi VD, Kuritzkes DR, Deeks SG, Perelson AS, Treatment-mediated alterations in HIV fitness preserve CD4+ T cell counts but have minimal effects on viral load. PLoS Comput Biol. 2010;6(11):e1001012. doi: 10.1371/journal.pcbi.1001012 21124866
33. Ribeiro RM, Qin L, Chavez LL, Li D, Self SG, Perelson AS, Estimation of the initial growth rate and basic reproduction number during acute HIV infection. J Virol. 2010;84:6096–6102. doi: 10.1128/JVI.00127-10 20357090
34. Archin NM, Vaidya NK, Kuruc JD, Liberty AL, Wiegand A, Kearney MF, et al. Immediate antiviral therapy appears to restrict resting CD4+ cell HIV-1 infection without accelerating the decay of latent infection. Proc Natl Acad Sci USA. 2012;109(24):9523–9528. doi: 10.1073/pnas.1120248109 22645358
35. Ramratnam B, Bonhoeffer S, Binley J, Hurley A, Zhang LQ, Mittler JE, et al. Rapid production and clearance of HIV-1 and hepatitis C virus assessed by large volume plasma apheresis. Lancet. 1999;354(9192):1782–1785. doi: 10.1016/S0140-6736(99)02035-8 10577640
36. de Boer RJ, Ribeiro RM, Perelson AS, Current estimates for HIV-1 production imply rapid viral clearance in lymphoid tissues. PLoS Comput Biol. 2010;6(9):e1000906. doi: 10.1371/journal.pcbi.1000906 20824126
37. Markowitz M, Louie M, Hurley A, Sun E, Di Mascio M, A novel antiviral intervention results in more accurate assessment of human immunodeficiency virus type 1 replication dynamics and T-Cell decay in vivo. J Virol. 2003;77(8):5037–5038. doi: 10.1128/JVI.77.8.5037-5038.2003 12663814
38. Hockett RD, Kilby JM, Derdeyn CA, Saag MS, Sillers M, Squires K, et al. Constant mean viral copy number per infected cell in tissues regardless of high, low, or undetectable plasma HIV RNA. J Exp Med. 1999;189(10):1545–1554. doi: 10.1084/jem.189.10.1545 10330433
39. Chen HY, Di Mascio M, Perelson AS, Ho DD, Zhang L, Determination of virus burst size in vivo using a single-cycle SIV in rhesus macaques. Proc Natl Acad Sci USA. 2007;104(48):19079–19084. doi: 10.1073/pnas.0707449104 18025463
40. Ho YC, Shan L, Hosmane NN, Wang J, Laskey SB, Rosenbloom DIS, et al. Replication-competent noninduced proviruses in the latent reservoir increase barrier to HIV-1 cure. Cell. 2013;155(3):540–551. doi: 10.1016/j.cell.2013.09.020 24243014
41. Andrade A, Guedj J, Rosenkranz SL, Lu D, Mellors J, Kuritzkes DR, et al. Early HIV RNA decay during raltegravir-containing regimes exhibits two distinct subphases (1a and 1b). AIDS. 2015;29:2419–2426. 26558541
42. Markowitz M, Nguyen Y B, Gotuzzo E, Mendo F, Ratanasuwan W, Kovacs C, et al. Sustained antiretroviral effect of raltegravir after 96 weeks of combination therapy in treatment-naive patients with HIV-1 infection. JAIDS. 2009;52:350–356. 19648823
43. McMahon D, Jones H, Wiegand A, Gange SJ, Kearney M, Palmer S, et al. Short-course raltegravir intensification does not reduce persistent low-level viremia in patients with HIV-1 suppression during receipt of combination antiretroviral therapy. Clin Infect Dis. 2010;50:912–919. doi: 10.1086/650749 20156060
44. Westera L, Drylewicz J, den Braber I, Mugwagwa T, van der Maas I, Kwast L, et al. Closing the gap between T-cell life span estimates from stable isotope-labeling studies in mice and humans. Blood. 2013;122:2205–2212. doi: 10.1182/blood-2013-03-488411 23945154
45. Guckenheimer J, P H, Nonlinear oscillations, dynamical systems, and bifurcations of vector fields. Springer; 1983.
46. Dornadula G, Zhang H, VanUitert B, Stern J, Livornese L, JrIngerman MJ, et al. Residual HIV-1 RNA in blood plasma of patients taking suppressive highly active antiretroviral therapy. J Amer Med Assoc. 1999;282:1627–32. doi: 10.1001/jama.282.17.1627
47. Gillespie DT, Exact stochastic simulation of coupled chemical reactions. J Phys Chem. 1977;81:2340–2361. doi: 10.1021/j100540a008
48. Farrington CP, Grant AD, The distribution of time to extinction in subcritical branching processes: applications to outbreaks of infectious disease. J Appl Probab. 1999;36:771–779. doi: 10.1239/jap/1032374633
49. Pinkevych M, Cromer D, Tolstrup M, Grimm DA, Cooper DA, Lewin SR, et al. HIV rebound from latency occurs on average every 5–8 days—implications for HIV remission. PLoS Pathog. 2015;11:e1005000. doi: 10.1371/journal.ppat.1005000 26133551
50. de Boer RJ, Homann D, Perelson AS, Different dynamics of CD4+ and CD8+ T cell responses during and after acute lymphocytic choriomeningitis virus infection. J Immunol. 2003;171:3928–3935. doi: 10.4049/jimmunol.171.8.3928 14530309
51. Rong L, Perelson AS, Modeling latently infected cell activation: viral and latent reservoir persistence, and viral blips in HIV-infected patients on potent therapy. PLoS Comput Biol. 2009;5:e1000533. doi: 10.1371/journal.pcbi.1000533 19834532
52. Mansky LM, Temin HM, Lower in vivo mutation rate of human immunodeficiency virus type 1 than that predicted from fidelity of purified reverse transcriptase. J Virol. 1995;69:5087–5094. 7541846
53. Rosenbloom DIS, Hill AL, Rabi SA, Siliciano RF, Nowak MA, Antiretroviral dynamics determines HIV evolution and predicts therapy outcome. Nat Med. 2012;18:1378–1385. doi: 10.1038/nm.2892 22941277
54. Hill AL, Rosenbloom DIS, Fu F, Nowak MA, Siliciano RF, Predicting the outcomes of treatment to eradicate the latent reservoir for HIV-1. Proc Natl Acad Sci USA. 2014;111:13475—13480. doi: 10.1073/pnas.1406663111 25097264
55. Ribeiro RM, Bonhoeffer S, Production of resistant HIV mutants during antiretroviral therapy. Proc Natl Acad Sci USA. 2000;97:7681–7686. doi: 10.1073/pnas.97.14.7681 10884399
56. Li JZ, Gallien S, Ribaudoc H, Heiseya A, Bangsberg DR, Kuritzkes DR, Incomplete adherence to antiretroviral therapy is associated with higher levels of residual HIV-1 viremia. AIDS. 2014;28:181–186. 24361679
57. Wagner TA, McKernan JL, Tobin NH, Tapia KA, Mullins JI, Frenkel LM, An increasing proportion of monotypic HIV-1 DNA sequences during antiretroviral treatment suggests proliferation of HIV-infected cells. J Virol. 2013;87:1770–1778. doi: 10.1128/JVI.01985-12 23175380
58. Wagner TA, McLaughlin S, Garg K, Cheung CY, Larsen BB, Styrchak S, et al. Proliferation of cells with HIV integrated into cancer genes contributes to persistent infection. Science. 2014;345:570–573. doi: 10.1126/science.1256304 25011556
59. Margolis D, Bushman F, Persistence by proliferation? Science. 2014;345:143–144. doi: 10.1126/science.1257426 25013050
60. Maldarelli F, Wu X, Su L, Simonetti FR, Shao W, Hill S, et al. Specific HIV integration sites are linked to clonal expansion and persistence of infected cells. Science. 2014;345:179–183. doi: 10.1126/science.1254194 24968937
61. Cohn LB, Silva IT, Oliveira TY, Rosales RA, Parrish EH, Learn GH, et al. HIV-1 Integration landscape during latent and active infection. Cell. 2015;160:420–432. doi: 10.1016/j.cell.2015.01.020 25635456